Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 3/2013

01-03-2013 | Original Paper

Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center

Authors: T. Zeller, K. Muenstedt, C. Stoll, J. Schweder, B. Senf, E. Ruckhaeberle, S. Becker, H. Serve, J. Huebner

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2013

Login to get access

Abstract

Purpose

About 40–50 % of cancer patients use complementary and alternative medicine (CAM). Women, and especially those with gynecological cancers, are more active in this field than men. The goal of our study was to estimate the likelihood of CAM use and the likelihood of interactions of CAM with cancer therapy in the setting of a gynecological outpatient clinic at a German Comprehensive Cancer Center (CCC).

Methods

One hundred consecutive gynecological outdoor patients of the CCC in Frankfurt am Main in Germany were interviewed with a standardized questionnaire on CAM use. An investigation on potential interactions was done by matching a scientific database systematically.

Results

Sixty-nine of the interviewed 100 women received chemotherapy, 23 endocrine therapy and 41 monoclonal antibodies. In total, 64 % used CAM, 48 % used at least one substance-bound CAM. In 17 out of those 48 cases (35 %), interactions were unlikely, whereas they were probable in 14 patients (29 %). Thus, a third of all patients in this study were in danger of interactions. More than half of all CAM users and three quarters of users of substance-bound CAM are at risk of interactions. This number is independent of whether the patient is taking chemotherapy, endocrine therapy or antibodies.

Conclusions

The frequency of CAM use we found is in line with international data from CCCs in the USA. To our knowledge, this is the first study publishing data on the frequency of potential interactions. Thus, an initiative to protect women from the dangers of uncontrolled CAM use is urgently needed. In the discussion, we propose a concept of how to achieve this aim.
Appendix
Available only for authorised users
Literature
go back to reference Cassileth BR, Lucarelli CD (2003) Herb-drug interactions in oncology. Brian C Decker, London Cassileth BR, Lucarelli CD (2003) Herb-drug interactions in oncology. Brian C Decker, London
go back to reference Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA (2004) Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. JCO 22(23):4810–4815CrossRef Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA (2004) Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. JCO 22(23):4810–4815CrossRef
go back to reference Eschiti VS (2007) Lesson from comparison of CAM use by women with female-specific cancers to others: it’s time to focus on interaction risks with CAM therapies. Integr Cancer Ther 6(4):313–344CrossRefPubMed Eschiti VS (2007) Lesson from comparison of CAM use by women with female-specific cancers to others: it’s time to focus on interaction risks with CAM therapies. Integr Cancer Ther 6(4):313–344CrossRefPubMed
go back to reference Henderson JW, Donatelle RJ (2003) The relationship between cancer locus of control and complementary and alternative medicine use by women diagnosed with breast cancer. Psychooncology 12(1):59–67CrossRefPubMed Henderson JW, Donatelle RJ (2003) The relationship between cancer locus of control and complementary and alternative medicine use by women diagnosed with breast cancer. Psychooncology 12(1):59–67CrossRefPubMed
go back to reference Henderson JW, Donatelle RJ (2004) Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10(1):52–57PubMed Henderson JW, Donatelle RJ (2004) Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10(1):52–57PubMed
go back to reference Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK (2007) Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life and preferences for decision making. JCO 25:548–554CrossRef Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK (2007) Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life and preferences for decision making. JCO 25:548–554CrossRef
go back to reference Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2011) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther [Epub ahead of print] PMID: 22019489 Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2011) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther [Epub ahead of print] PMID: 22019489
go back to reference Micke O, Bruns F, Glatzel M, Schönekaes K, Micke P, Mücke R, Büntzel J (2009) Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med 1:22–30 Micke O, Bruns F, Glatzel M, Schönekaes K, Micke P, Mücke R, Büntzel J (2009) Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med 1:22–30
go back to reference Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, Bruyns I, Fernadez-Ortega P, Panteli V, Margulies A, Gudmundsdottir G, Milovics L, Ozden G, Platin N, Patiraki E (2006a) Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 14(3):260–267CrossRefPubMed Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, Bruyns I, Fernadez-Ortega P, Panteli V, Margulies A, Gudmundsdottir G, Milovics L, Ozden G, Platin N, Patiraki E (2006a) Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 14(3):260–267CrossRefPubMed
go back to reference Molassiotis A, Browall M, Milovics L, Panteli V, Patiraki E, Fernandez-Ortega P (2006b) Complementary and alternative medicine use in patients with gynecological cancers in Europe. Int J Gynecol Cancer 16(Suppl 1):219–224CrossRefPubMed Molassiotis A, Browall M, Milovics L, Panteli V, Patiraki E, Fernandez-Ortega P (2006b) Complementary and alternative medicine use in patients with gynecological cancers in Europe. Int J Gynecol Cancer 16(Suppl 1):219–224CrossRefPubMed
go back to reference Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R (2011) Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. Cancer 117(22):5142–5150CrossRefPubMed Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R (2011) Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. Cancer 117(22):5142–5150CrossRefPubMed
go back to reference Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18(13):2505–2514PubMed Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18(13):2505–2514PubMed
go back to reference Robinson A, McGrail MR (2004) Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 12(2-3):90–98CrossRefPubMed Robinson A, McGrail MR (2004) Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 12(2-3):90–98CrossRefPubMed
go back to reference Saxe GA, Madlensky L, Kealey S, Wu DP, Freeman KL, Pierce JP (2008) Disclosure to physicians of CAM use by breast cancer patients: findings from the women‘s healthy eating and living study. Integr Cancer Ther 7(3):122–127CrossRefPubMed Saxe GA, Madlensky L, Kealey S, Wu DP, Freeman KL, Pierce JP (2008) Disclosure to physicians of CAM use by breast cancer patients: findings from the women‘s healthy eating and living study. Integr Cancer Ther 7(3):122–127CrossRefPubMed
go back to reference Sparber A, Bauer L, Curt G, Eisenberg D, Levin T, Parks S, Steinberg SM, Wootton J (2000) Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 27(4):623–630PubMed Sparber A, Bauer L, Curt G, Eisenberg D, Levin T, Parks S, Steinberg SM, Wootton J (2000) Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 27(4):623–630PubMed
go back to reference Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26(4):665–673CrossRefPubMed Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26(4):665–673CrossRefPubMed
Metadata
Title
Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center
Authors
T. Zeller
K. Muenstedt
C. Stoll
J. Schweder
B. Senf
E. Ruckhaeberle
S. Becker
H. Serve
J. Huebner
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 3/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-012-1336-6

Other articles of this Issue 3/2013

Journal of Cancer Research and Clinical Oncology 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.